Archinla: Thanks for your comments. I am a buy and hold type of investor about 95% of the time. I buy the science. I figure if the science has potential, someone at the company will figure out how to capitalize on it someday. I'm still waiting with AVII and CYGX. But I bought in at the right time and I'm profitable on both. The reason I don't do quick trades is that I am just too busy. I only have time to look at the market for a few minutes a day, at least on most days. I work as a clinical pharmacist 3 days a week at a fairly busy Chicago hospital. I am trying to fix up a 100 year old house to maximize the resale value before we try to sell next spring. I'm training to climb Mt Kilimanjaro in February. I'm executor on an estate, and that has been time intensive. I had a good feeling that AVII would do a PIPE after the "pump"...it is the way they do business. Many small biotechs do the same thing. It is something I have to live with as a long term investor. I'm hoping for one or two home runs. That is all you need. I had a few big winners in the past and just didn't have enough shares to make "walk away" money. But, I'm not 50 years old yet and I only work part time (mainly for the health care benefits). I hope CYGX will be one of my big winners. I'm giving the management until the end of the year to produce some positive news that brings in some money and drives the share price up. If Malcolm and his cronies keep up the complete secrecy beyond the end of the year I'm going to bail and look around for another investment opportunity. I just don't think that is the way you should treat your shareholders and the general investment public. Blind Faith was a great rock group from the early 70's, it is not an investment strategy.
Are you a "trader"? If so, what is your track record? What other companies do you follow? I have thought AVII could be a possible bird flu "play" for several years, long before the current hype about a possible pandemic. Their science is absolutley cutting edge 21st century medicine. Genome to compound in days. Days!. Such a "rapid response" technology could revolutionize viral treatment. If their Hepatitic C drug proves successful that would make 2 potential blockbusters. Amgen made an absolute fortune on 2 drugs....Epogen and Neupogen. If AVII's share price would rise 1/10th the rise Amgen has seen in 17 years I'd be a lot richer. Such is the enduring hope of the speculative biotech investor. Have a good rest of the weekend.
AI
Market Data 
Markets 
